At 8.9% CAGR, the Middle East & Africa Lyophilization Services for Biopharmaceuticals Market is projected to be worth US$ 97.55 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa lyophilization services for biopharmaceuticals market was valued at US$ 63.68 million in 2023 and is expected to reach US$ 97.55 million by 2028, registering a CAGR of 8.9% from 2023 to 2028. Rising demand for lyophilized products and rapid growth in contract manufacturing and lyophilization services are among the critical factors attributed to the Middle East & Africa lyophilization services for biopharmaceuticals market expansion.             

There is a lot of scope for applying RNA interference (RNAi) for cancer treatment. RNAi has become a powerful technology for gene function studies and can be used in therapeutic applications. Moreover, after more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine, from target development to technological improvement. The development of a successful subcutaneous antibody therapy requiring chronic administration at high dosing, particularly when coupled with a prefilled syringe and autoinjector device for at-home administration, depends on the development of a stable formulation at high concentration. To avoid the instability of the aqueous antibody solution, products are stored in a lyophilized (freeze-dried) state. These compounds regularly require freeze-drying to maintain the integrity of the formulation or vehicle to target the small interfering RNA (siRNA) in the body. The long-term stability of therapeutic candidates is necessary for their clinical applications. For most nanoparticle systems formulated in aqueous solutions, lyophilization or freeze-drying is a standard method to ensure long-term stability. Therefore, the rising number of siRNA and antibody-based formulations is expected to become a prevalent trend in the Middle East & Africa lyophilization services for biopharmaceuticals market in the coming years.

On the contrary, demerits associated with lyophilization process hampers on the growth of Middle East & Africa lyophilization services for biopharmaceuticals market. 

Based on service type, the Middle East & Africa lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. The commercial manufacturing segment held 29.5% share of Middle East & Africa lyophilization services for biopharmaceuticals market in 2023, amassing US$ 18.75 million. It is projected to garner US$ 27.11 million by 2028 to expand at 7.6% CAGR during 2023–2028.

Based on end user, the Middle East & Africa lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and other. The pharmaceutical & biotechnology companies segment held 76.4% share of Middle East & Africa lyophilization services for biopharmaceuticals market in 2023, amassing US$ 48.65 million. It is projected to garner US$ 75.19 million by 2028 to expand at 9.1% CAGR during 2023–2028.

Based on country, the Middle East & Africa lyophilization services for biopharmaceuticals market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 39.3% share of Middle East & Africa lyophilization services for biopharmaceuticals market in 2023. It was assessed at US$ 25.03 million in 2023 and is likely to hit US$ 37.21 million by 2028, exhibiting a CAGR of 8.2% during 2023–2028.            

Key players operating in the Middle East & Africa lyophilization services for biopharmaceuticals market are ABB, Azbil Corporation, Busch, LLC, Curia Global Inc, Jubilant HollisterStier LLC., and Labconco, among others.